What changes to pricing guidelines mean for drugs in Canada
After multiple delays, the PMPRB (Patented Medicine Prices Review Board) is expected to implement revised guidelines within 2022, which include an update to...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Price and access decisions are critical for maximizing the lifecycle value of an asset or franchise. Life sciences companies seeking to develop successful pricing and access strategies must navigate the complex and evolving interactions between customers and products, and must ensure that their decisions balance strategic and financial goals while enabling appropriate access and reimbursement to medical providers, patients, and caregivers.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comAfter multiple delays, the PMPRB (Patented Medicine Prices Review Board) is expected to implement revised guidelines within 2022, which include an update to...
This article was originally published in PharmaPhorum. In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice...